ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company strategy. Management to host a conference call today at 8:00am EDT (14:00 CET).
… type 10 (LCA10) ARVO 2021 presentation by Stephen R. Russell from Iowa University on the Safety and efficacy of … Leber Congenital Amaurosis type 10. Author(s) Stephen R. Russell 1 , Arlene V. Drack 1 , Artur V. Cideciyan 2 , … The Children’s Hospital of Philadelphia, PA, USA; 5 ProQR Therapeutics, Leiden, the Netherlands …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… Ho 1 , Artur V Cideciyan 2 , Samuel G Jacobson 2 , Stephen R Russell 3 , Arlene V Drack 3 , Bart P Leroy 4, 5, 6 , Michael R Schwartz 7 , Wilhelmina den Hollander 7 , Hsin Yi Huang van … Hospital of Philadelphia, Philadelphia, Pennsylvania; 7 ProQR Therapeutics, Leiden, the Netherlands. Ho A, Cideciyan …
